Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Only health care professionals may attend this satellite symposium.

Dinner will be provided.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.

Statement of Need/Program Overview

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.^1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.^3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.^5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.^7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will stand to benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.

References

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
3. Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7 [Epub ahead of print].
4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
5. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
6. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
7. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
8. de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
9. Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
10. Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

• Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
• Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
• Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
• Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
• Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Integritas Communications at info@integritasgrp.com

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.